13F Holdings
中文EN

OCS Oculis Holding AG IFRS

Pharmaceutical Preparations · Nasdaq · SEC CIK 1953530 · Reporting currency CHF · Fiscal year ends 12/31

Financial factors as of 2025-12-31 (FY2025), by fiscal year; growth vs the previous fiscal year

Growth

TTM revenue YoY—
TTM net income YoY-15.4%
TTM EPS YoY10.8%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-73.5%
ROA-55.5%
ROIC (approx.)-80.4%
Asset turnover—

Leverage & solvency

Liabilities / assets16.9%
Debt / equity0.00x
Current ratio5.96x
Interest coverage-98.05x

Cash quality & payout

Operating cash flow / net income0.67x
Accruals ratio-18.3%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Unit: CHF FY2025*2025-12-31FY2024*2024-12-31FY2023*2023-12-31FY2022*2022-12-31FY2021*2021-12-31
Income statement
Revenue—————
R&D expense57.09M52.08M29.25M22.22M9.57M
SG&A expense25.79M21.81M17.49M11.06M4.62M
Operating income-81.67M-73.20M-80.71M-32.38M-13.23M
Interest expense833,000639,0001.31M6.44M5.12M
Pretax income-99.14M-85.94M-88.69M-38.64M-18.52M
Income tax-186,000-160,000107,00055,00027,000
Net income-98.96M-85.78M-88.80M-38.70M-18.55M
EPS (basic)-1.89-2.12-2.97-11.32-5.84
EPS (diluted)-1.89-2.12-2.97-11.32-5.84
Weighted avg. shares (diluted)52.24M40.41M29.90M2.99M2.78M
Banking
Net interest income———126,00021,000
Balance sheet
Cash & equivalents81.33M27.71M38.33M19.79M46.28M
Current assets218.89M104.90M101.02M23.66M47.98M
PP&E, netmay include right-of-use assets (IFRS)534,000385,000288,000365,000431,000
Intangibles13.29M13.29M12.21M12.21M8.72M
Total assets235.96M120.35M114.35M37.06M58.04M
Current liabilities36.75M44.23M19.09M12.02M4.06M
Total liabilities39.89M46.97M20.62M135.05M119.00M
Shareholders' equity196.07M73.38M93.73M-97.99M-60.95M
Shares outstanding———3.41M—
Cash flow statement
Operating cash flow-66.30M-48.92M-55.04M-25.07M-13.82M
Capital expenditure301,000230,00048,00065,00028,000
Free cash flow-66.61M-49.15M-55.09M-25.14M-13.85M
Investing cash flow-60.93M-16.08M-52.97M-3.55M-28,000
Financing cash flow186.92M53.98M129.63M1.71M55.19M
Stock-based compensation16.04M9.78M3.61M804,000328,000

Free plan shows the latest 5 periods; Pro shows all 6 🔒

· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.

· This company does not report gross profit in XBRL.

· Amounts are in the company's reporting currency, CHF, not USD; the site does no currency conversion.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.